ストックスクリーナーアプリを入手
16.64
3.66%
0.5858
Pharvaris Nv (PHVS) 最新ニュース
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush | PHVS Stock News - GuruFocus
Citizens JMP reiterates Market Outperform rating for Pharvaris stock By Investing.com - Investing.com UK
Transcript : Pharvaris N.V.Special Call - marketscreener.com
Pharvaris reports promising results for deucrictibant in HAE By Investing.com - Investing.com UK
Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
How To Trade (PHVS) - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World
Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World
Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World
Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World
The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World
Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus
Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus
Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus
Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com
(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan
Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World
When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com
Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World
Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World
Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target - marketscreener.com
JMP reiterates Pharvaris stock with $55 target, positive outlook By Investing.com - Investing.com UK
Where are the Opportunities in (PHVS) - news.stocktradersdaily.com
What is Leerink Partnrs’ Forecast for Pharvaris Q1 Earnings? - The AM Reporter
5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World
What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World
Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World
What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView
Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks
Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan
Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World
(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener
Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan
(PHVS) Technical Data - news.stocktradersdaily.com
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
1.30%
3.35%
大文字化:
|
ボリューム (24 時間):